Table 1 Characteristics of the included studies
Year | Author | Region | Treatment | Tumour | Number of patients | Outcomes | Sex (male/fem ale) | Newcastle-Ottawa scale | Study design* |
|---|---|---|---|---|---|---|---|---|---|
2023 | Tao Sun | China | camrelizumab | HCC | 224 | OS; PFS; ORR; DCR | 182/42 | 7 | R |
2023 | Magdalena Knetki-Wróblewska | Poland | nivolumab or atezolizumab | advanced NSCLC | 260 | OS; PFS | 149/111 | 7 | R |
2023 | Jingyuan Xie | China | anti-PD-1 or anti-PD-L1 | extensive-stage small cell lung cancer | 116 | OS; PFS | 106/10 | 7 | R |
2023 | Pauline Parent | France, Spain, Belgium, and other | anti-PD1 and anti‐PDL1 (ICI cohort) | advanced or metastatic urinary tract carcinoma | 137 | OS; PFS | 112/25 | 7 | R |
2023 | Pauline Parent | France, Spain, Belgium, and other | atezolizumab (SAUL cohort) | advanced or metastatic urinary tract carcinoma | 541 | OS; PFS; ORR; DCR | 408/133 | 8 | P |
2023 | Omer Diker | Nicosia | / | NSCLC | 150 | OS; PFS; ORR | 131/19 | 6 | R |
2023 | Javier García-Corbacho | Spain | / | advanced solid tumours | 146 | OS; PFS; ORR | / | 7 | P |
2023 | Andrea De Giglio | Italy | / | advanced NSCLC | 183 | OS | 114/69 | 7 | R |
2023 | Monica Pierro | France | pembrolizumab, nivolumab, atezolizumab, and, avelumab | solid tumours | 191 | OS; PFS; ORR; irAEs | 117/74 | 7 | R |
2023 | Yusuke Inoue | Japan | atezolizumab | NSCLC | 69 | OS; PFS | / | 7 | P |
2022 | Miaomiao Gou | China | nivolumab, pembrolizumab, sintilimab, and, toripalimab | metastatic gastric cancer | 186 | OS | 132/54 | 7 | R |
2022 | Kei Sonehara | Japan | nivolumab, pembrolizumab, and, atezolizumab | NSCLC | 113 | irAEs | 91/22 | 7 | R |
2022 | Jia Chen | China | pembrolizumab, nivolumab, sintilimab, and, toripalimab. | advanced NSCLC | 85 | OS; PFS | 62/23 | 6 | R |
2022 | Ana Ortega-Franco | UK | pembrolizumab | NSCLC | 113 | OS; PFS; ORR; DCR | 67/46 | 7 | R |
2022 | Jean-Baptiste Assié | French | nivolumab | malignant pleural mesothelioma | 109 | OS | 74/35 | 7 | R |
2022 | Shiyun Chen | China | nivolumab, pembrolizumab, and, sintilimab | pancreatic carcinoma | 98 | OS; PFS | 70/28 | 7 | R |
2022 | Yuji Uehara | Japan | ICI-monotherapy | NSCLC | 80 | PFS | 62/18 | 6 | R |
2022 | Yuji Uehara | Japan | ICI-chemotherapy | NSCLC | 80 | PFS | 62/18 | 6 | R |
2022 | Yuting Pan | China | nivolumab, toripalimab, sintilimab, and, pembrolizumab | advanced bile tract carcinoma | 110 | OS; PFS | 67/43 | 6 | R |
2021 | G Mountzios | Greece and Germany | ICI-monotherapy | advanced NSCLC | 206 | OS; PFS | 125/81 | 7 | R |
2021 | G Mountzios | Greece and Germany | ICI-chemotherapy | advanced NSCLC | 206 | OS; PFS | 125/81 | 7 | R |
2021 | Edouard Auclin | France and Spain | atezolizumab, avelumab, nivolumab, ipilimumab, and, pembrolizumab | mismatch repair deficient tumours | 151 | OS; PFS | 62/89 | 7 | R |
2021 | Wael Abdullah Sultan Ali | China | pembrolizumab, nivolumab, camrelizumab, and, atezolizumab | NSCLC | 73 | OS; PFS | 51/22 | 6 | R |
2021 | Jiamin Sheng | China | pembrolizumab, nivolumab, atezolizumab, and, sintilimab | NSCLC | 41 | OS; PFS | 28/13 | 6 | R |
2021 | Baicun Hou | China | / | advanced gastric cancer | 120 | OS; PFS; ORR; DCR | 80/40 | 7 | R |
2021 | Antonello Veccia | Italy | pembrolizumab | NSCLC | 117 | ORR; DCR | 78/39 | 6 | R |
2021 | Heidi A I Grosjean | Canada | pembrolizumab | PD-L1 Positive NSCLC | 327 | OS | 157/170 | 7 | P |
2021 | Ashley M Hopkins | Australia | atezolizumab (ABCP) | advanced NSCLC | 400 | OS; PFS | 240/160 | 7 | P |
2021 | Ashley M Hopkins | Australia | atezolizumab (ABP) | advanced NSCLC | 402 | OS; PFS | 241/161 | 7 | P |
2021 | Lingling Li | China | anti-PD-1 or anti-PD-L1 | advanced small cell lung cancer | 100 | OS; PFS | 88/12 | 6 | R |
2020 | G Mazzaschi | Italy | pembrolizumab, nivolumab, and, atezolizumab | NSCLC | 109 | OS | 73/36 | 7 | P |
2020 | Ghassan Al Darazi | France | / | solid tumour | 259 | OS | 169/90 | 7 | P |
2020 | Wenxian Wang | China | ICI-monotherapy | NSCLC | 216 | OS; PFS | 179/39 | 6 | R |
2020 | Wenxian Wang | China | ICIs combined with chemotherapy | NSCLC | 114 | OS; PFS | 98/16 | 6 | R |
2020 | Shixue Chen | China | nivolumab, pembrolizumab, and, other | HCC | 108 | OS; PFS | 90/18 | 7 | R |
2019 | Juan Ruiz-Bañobre | Spain | nivolumab | advanced NSCLC | 153 | OS; PFS; ORR | 119/34 | 7 | R |
2019 | Daniel E Meyers | Canada | nivolumab, pembrolizumab, and, ipilimumab/nivolumab | NSCLC, RCC, and melanoma | 578 | OS; PFS; ORR | / | 7 | R |
2019 | Michael J Sorich | Australia | atezolizumab | advanced NSCLC | 1489 | OS; PFS | / | 7 | P |
2019 | Dickran Kazandjian | USA | / | / | 1368 | OS; PFS | / | 7 | P |
2018 | Laura Mezquita | Europe | nivolumab, pembrolizumab, atezolizumab, durvalumab, and, durvalumab-ipilimumab | NSCLC | 431 | ORR; DCR | 301/130 | 7 | R |